Altria
MO
$74.21
+1.62%
Altria Group, Inc. is a leading U.S. tobacco company that manufactures and sells cigarettes, smokeless tobacco, cigars, and reduced-risk products through subsidiaries including Philip Morris USA and U.S. Smokeless Tobacco. The company holds the dominant position in the U.S. cigarette market with the Marlboro brand commanding a 40% share, and also has a significant presence in smokeless tobacco and machine-made cigars. The current investor narrative centers on Altria's transition toward smoke-free products, including its Njoy vaping acquisition and heated tobacco joint venture, while its traditional cigarette business faces secular decline. Recent attention has focused on the company's strong dividend yield and potential payout increases, balanced against regulatory risks and the pace of its reduced-risk product adoption.…
MO
Altria
$74.21
Related headlines
Investment Opinion: Should I buy MO Today?
Rating: Hold. Altria is a high-yield income stock with defensive qualities, but limited near-term upside and structural headwinds warrant a cautious stance. The analyst consensus is 'hold' with an average target of $70.64, implying negligible upside.
Supporting Evidence: Altria's trailing P/E of 14.0x is below the industry median of 18x, suggesting undervaluation. Revenue grew 20.1% YoY in Q1 2026, though partly due to price increases. Net margin of 40.2% and free cash flow of $8.6 billion demonstrate strong profitability. The dividend yield of 7.2% is well above the S&P 500 average. However, the forward P/E of 12.0x implies only modest earnings growth expectations.
Risks & Conditions: The Hold rating would upgrade to Buy if the stock pulls back to $60 or below (near the 52-week low), offering a higher margin of safety, or if smoke-free product adoption accelerates significantly. A downgrade to Sell would occur if the dividend is cut or if regulatory actions materially impact earnings. Overall, Altria appears fairly valued relative to its history and peers, given the risks.
Sign up to view all
MO 12-Month Price Forecast
Altria's outlook is balanced between its high income generation and structural decline. The base case of a range-bound stock with a 7.2% yield is most probable, given the slow pace of smoke-free adoption. The bull case requires meaningful progress in reduced-risk products, while the bear case hinges on regulatory action. The neutral stance reflects the lack of a clear catalyst to drive the stock significantly higher or lower from current levels. An upgrade to bullish would require evidence of accelerating smoke-free revenue; a downgrade to bearish would follow a dividend cut or menthol ban.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $70.64 and implied upside of -4.8% versus the current price.
Average Target
$70.64
0 analysts
Implied Upside
-4.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$59 - $82
Analyst target range
Altria is covered by 11 analysts, with a consensus recommendation of 'hold' (mean recommendation 2.62 on a 1-5 scale where 1 is strong buy). The average target price is $70.64, implying a negligible upside of 0.2% from the current price of $70.52. The distribution shows a mix of ratings: recent actions include UBS (Buy), Barclays (Underweight), Citigroup (Neutral), and Stifel (Buy), indicating a lack of strong consensus. The target price range spans from a low of $59.00 to a high of $82.00. The high target of $82.00 assumes successful execution of the smoke-free strategy and potential multiple expansion, while the low target of $59.00 prices in continued volume declines and regulatory headwinds. The wide spread of $23.00 (39% of the low target) signals high uncertainty about the company's future trajectory. Recent analyst actions show no major upgrades or downgrades, with most firms maintaining their previous ratings. The 'hold' consensus reflects the stock's defensive appeal and dividend yield balanced against structural challenges in the tobacco industry.
Bulls vs Bears: MO Investment Factors
Altria presents a classic value trap versus value opportunity debate. The bull case rests on its 7.2% dividend yield, strong free cash flow, and attractive valuation at 14x trailing earnings, which is below the industry average. The bear case highlights secular volume declines, regulatory overhangs, and a balance sheet with negative equity. Currently, the evidence slightly favors the bull case given the stock's defensive performance and high income generation, but the key tension is whether Altria's smoke-free transition can offset cigarette declines. If Njoy and heated tobacco gain meaningful traction, the stock could re-rate higher; if not, the dividend may become unsustainable.
Bullish
- High Dividend Yield with Payout Growth Potential: Altria offers a 7.2% dividend yield, one of the highest in the S&P 500, and the payout ratio is 100.2%, indicating earnings fully cover the dividend. Recent news highlights potential payout increases this summer, supported by strong earnings growth and low payout ratios relative to cash flow.
- Strong Profitability and Cash Flow: Altria's Q1 2026 net margin was 40.2%, and operating margin was 54.5%, reflecting exceptional pricing power. Trailing twelve-month free cash flow is $8.6 billion, providing ample coverage for dividends and debt service.
- Attractive Valuation Relative to Peers: The trailing P/E of 14.0x and forward P/E of 12.0x are below the tobacco industry median of ~18x, suggesting the stock is undervalued. The EV/EBITDA of 10.9x is reasonable for a cash-generative business.
- Defensive Characteristics with Low Beta: With a beta of 0.49, Altria is significantly less volatile than the market, making it a defensive holding that tends to hold up well during downturns. The stock is up 20.6% over the past year, near its 52-week high.
Bearish
- Secular Decline in Cigarette Volumes: U.S. cigarette consumption has been declining at 3-5% annually, and Altria's smokeable products revenue still dominates at $4.76 billion in Q1 2026. The company's transition to smoke-free products is still nascent, with Njoy and heated tobacco facing stiff competition.
- Regulatory and Litigation Risks: The FDA's potential menthol ban and flavor restrictions could significantly impact Marlboro volumes. Additionally, ongoing litigation and settlement costs pose financial risks, as seen in the $258 million quarterly interest expense from debt.
- Negative Shareholders' Equity and High Debt: Altria's debt-to-equity ratio is -7.34 due to negative equity of -$3.5 billion, a result of years of share buybacks and debt accumulation. The current ratio of 0.61 indicates low short-term liquidity, though cash flow covers obligations.
- Limited Upside to Analyst Targets: The average analyst target of $70.64 implies only 0.2% upside from the current price of $70.52. The consensus rating is 'hold,' reflecting a lack of strong conviction among analysts.
MO Technical Analysis
Altria is in a sustained uptrend, with the stock price up 20.6% over the past year and currently trading at $70.52, which is 94.6% of its 52-week range ($54.70 low to $74.56 high). This positioning near the top of the range suggests strong bullish momentum, though it also raises caution about potential overextension given the stock's proximity to resistance. The 1-year relative strength versus SPY is slightly negative at -0.33%, indicating that while MO has risen, it has slightly underperformed the broader market over the long term. Short-term momentum is accelerating: the 1-month price change is +1.34% and the 3-month change is +8.59%, both positive and consistent with the longer-term uptrend. The 1-month relative strength versus SPY is +0.74%, showing that MO has modestly outperformed the market recently. The stock's beta of 0.49 indicates it is significantly less volatile than the S&P 500, making it a defensive holding that tends to hold up better during market downturns. The 52-week high of $74.56 serves as key resistance; a breakout above this level would signal continued bullish momentum and potentially open the door to further gains. Conversely, the 52-week low of $54.70 provides support, and a breakdown below that level would suggest a bearish reversal. The short ratio of 5.95 days indicates moderate bearish sentiment among short sellers, which could fuel a short squeeze if the uptrend persists.
Beta
0.49
0.49x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$75
Price range past year
Annual Return
+28.0%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | +7.6% | +0.3% |
| 3m | +15.6% | +4.7% |
| 6m | +20.2% | +7.5% |
| 1y | +28.0% | +18.4% |
| ytd | +29.5% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Altria's revenue trajectory is growing, with Q1 2026 revenue of $5.428 billion representing a 20.1% year-over-year increase from Q1 2025's $4.519 billion. However, this growth is partly driven by price increases and mix shifts, as smokeable products revenue of $4.758 billion still dominates, while smokeless products contributed $669 million. The multi-quarter trend shows revenue fluctuating: Q4 2025 was $5.846 billion, Q3 2025 was $5.251 billion, and Q2 2025 was $5.290 billion, indicating some variability but an overall upward trajectory. The company is highly profitable, with Q1 2026 net income of $2.183 billion and a net margin of 40.2%. Gross margin was 64.6% in Q1 2026, down from 72.8% in Q2 2025, likely due to product mix shifts and cost pressures. Operating margin was 54.5% in Q1 2026, reflecting strong pricing power and efficient operations. The trailing twelve-month free cash flow is $8.623 billion, demonstrating robust cash generation. Altria's balance sheet shows a debt-to-equity ratio of -7.34, which is negative due to negative shareholders' equity (a common feature for tobacco companies with large debt and share buybacks). The current ratio of 0.61 indicates low short-term liquidity, but the company's strong operating cash flow ($2.324 billion in Q1 2026) and free cash flow ($2.231 billion) provide ample coverage for dividends and debt service. The ROE is negative (-198.4%) due to negative equity, but ROA of 27.6% is strong, indicating efficient asset utilization.
Quarterly Revenue
$5.4B
2026-03
Revenue YoY Growth
+20.1%
YoY Comparison
Gross Margin
64.6%
Latest Quarter
Free Cash Flow
$8.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 14.0x, while the forward P/E is 12.0x, implying that the market expects earnings growth over the next year. The gap between trailing and forward P/E suggests a modest growth expectation, consistent with a mature but stable company. Compared to the industry average (Consumer Defensive/Tobacco), Altria's P/E of 14.0x is at a discount to the sector median of approximately 18x, based on typical tobacco valuations. This discount may reflect the secular decline in cigarette volumes and regulatory overhangs, but it also suggests potential value if the company's smoke-free transition gains traction. Historically, Altria's trailing P/E has ranged from roughly 7x to 24x over the past five years. The current 14.0x is near the middle of this range, indicating that the stock is neither excessively cheap nor expensive by its own historical standards. The P/S ratio of 4.8x is also moderate relative to historical levels, which have ranged from 13x to 22x, but note that the current P/S is lower due to higher revenue. The EV/EBITDA of 10.9x is reasonable for a cash-generative business.
PE
14.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Altria's balance sheet is strained, with a debt-to-equity ratio of -7.34 due to negative shareholders' equity of approximately $3.5 billion. The current ratio of 0.61 indicates low short-term liquidity, though the company generates $8.6 billion in trailing free cash flow, which covers its $5.1 billion annual dividend. Gross margin compression from 72.8% in Q2 2025 to 64.6% in Q1 2026 signals potential cost pressures or product mix shifts that could erode profitability. The payout ratio of 100.2% leaves little room for error; any earnings decline could force a dividend cut.
Market & Competitive Risks: Altria faces secular decline in cigarette volumes, with U.S. consumption falling 3-5% annually. The FDA's potential menthol ban could accelerate this trend, directly impacting Marlboro's 40% market share. Competition from British American Tobacco's Vuse and Juul in vaping, as well as Philip Morris International's IQOS, threatens Altria's smoke-free ambitions. The stock's beta of 0.49 provides some insulation from macro volatility, but rising interest rates could make its 7.2% yield less attractive relative to risk-free alternatives.
Worst-Case Scenario: A combination of a menthol ban, accelerated volume declines, and failure of the smoke-free strategy could lead to earnings deterioration and a dividend cut. In this scenario, the stock could fall to its 52-week low of $54.70, representing a 22.4% decline from the current price of $70.52. The analyst low target of $59.00 implies a 16.3% downside. Historical max drawdown of 19.15% suggests a realistic worst-case loss of about 20%.
FAQ
The primary risk is regulatory: a menthol ban by the FDA could significantly impact Marlboro sales, which account for 40% of the U.S. cigarette market. Second, secular volume declines of 3-5% annually erode the core business, and the smoke-free transition may not offset this. Third, the balance sheet is weak, with negative equity and a debt-to-equity ratio of -7.34, though cash flow covers debt service. Fourth, the payout ratio of 100.2% leaves no buffer; any earnings decline could force a dividend cut, which would likely cause a sharp stock price drop. The most severe risk is a dividend cut, which could send the stock to its 52-week low of $54.70.
The 12-month outlook is mixed. The base case (50% probability) sees the stock trading in a $65-$75 range, supported by the 7.2% dividend yield but limited by slow smoke-free adoption. The bull case (25% probability) targets $74.56-$82.00, driven by successful Njoy traction and a dividend increase. The bear case (25% probability) sees the stock falling to $54.70-$59.00 if a menthol ban or dividend cut materializes. The average analyst target of $70.64 suggests the stock is fairly valued. The most likely scenario is the base case, with the stock providing a total return of 7-8% from dividends and modest price appreciation.
Altria appears undervalued relative to its industry, with a trailing P/E of 14.0x versus the tobacco sector median of approximately 18x. The forward P/E of 12.0x implies expected earnings growth, which is modest but positive. Historically, MO's P/E has ranged from 7x to 24x over the past five years, so the current 14x is near the middle, indicating fair value. The P/S ratio of 4.8x is also moderate. The market is pricing in the secular decline in cigarettes and regulatory risks, which explains the discount. If the smoke-free transition gains traction, the stock could re-rate higher.
Altria is a good buy for income-focused investors seeking a high dividend yield of 7.2% with defensive characteristics. The stock's trailing P/E of 14.0x is below the industry average, suggesting value, and its low beta of 0.49 provides stability. However, the average analyst target of $70.64 implies only 0.2% upside, and the consensus is 'hold,' reflecting limited near-term catalysts. The biggest risk is a dividend cut if cigarette volumes decline faster than expected. For long-term income investors, MO can be a solid addition, but growth-oriented investors may find better opportunities elsewhere.
Altria is best suited for long-term investment, particularly for income-oriented investors. Its low beta of 0.49 and high dividend yield of 7.2% make it a defensive holding that can provide steady income over time. Short-term trading is less attractive given the limited upside to analyst targets and the stock's low volatility. The company's strong cash flow and dominant market position support dividend sustainability, but secular decline means capital appreciation is unlikely. A minimum holding period of 3-5 years is recommended to ride out regulatory and volume headwinds and benefit from the dividend yield.